On the basis of these biological effects, this pilot study assessed the feasibility and potential efficacy of CCR2 inhibition by PG in terms of albuminuria as well as HbA1c and CRP levels in patients with type 2 diabetes and nephropathy. Here, CRP is linked to kidney disorder.